Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19
Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19
ABSTRACT BACKGROUNDAs the coronavirus disease 2019 (COVID-19) pandemic continues and millions remain vulnerable to infection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), attention has turned to characterizing post-acute sequelae of SARS-CoV-2 infection (PASC). METHODSFrom April 21 to December 31, 2020, we assembled a cohort of consecutive volunteers who a) had documented history of SARS-CoV-2 RNA-positivity; b) were ≥ 2 weeks past onset of COVID-19 symptoms or, if asymptomatic, first test for SARS-CoV-2; and c) were able to travel to our site in San Francisco. Participants learned about the study by being identified on medical center-based registries and being notified or by responding to advertisements. At 4-month intervals, we asked participants about physical symptoms that were new or worse compared to the period prior to COVID-19, mental health symptoms and quality of life. We described 4 time periods: 1) acute illness (0-3 weeks), 2) early recovery (3-10 weeks), 3) late recovery 1 (12-20 weeks), and 4) late recovery 2 (28-36 weeks). Blood and oral specimens were collected at each visit. RESULTSWe have, to date, enrolled 179 adults. During acute SARS-CoV-2 infection, 10 had been asymptomatic, 125 symptomatic but not hospitalized, and 44 symptomatic and hospitalized. In the acute phase, the most common symptoms were fatigue, fever, myalgia, cough and anosmia/dysgeusia. During the post-acute phase, fatigue, shortness of breath, concentration problems, headaches, trouble sleeping and anosmia/dysgeusia were the most commonly reported symptoms, but a variety of others were endorsed by at least some participants. Some experienced symptoms of depression, anxiety, and post-traumatic stress, as well as difficulties with ambulation and performance of usual activities. The median visual analogue scale value rating of general health was lower at 4 and 8 months (80, interquartile range [IQR]: 70-90; and 80, IQR 75-90) compared to prior to COVID-19 (85; IQR 75-90). Biospecimens were collected at nearly 600 participant-visits. CONCLUSIONAmong a cohort of participants enrolled in the post-acute phase of SARS-CoV-2 infection, we found many with persistent physical symptoms through 8 months following onset of COVID-19 with an impact on self-rated overall health. The presence of participants with and without symptoms and ample biological specimens will facilitate study of PASC pathogenesis. Similar evaluations in a population-representative sample will be needed to estimate the population-level prevalence of PASC.
Pineda-Ramirez Jesus、Yuan Yan、Rutishauser Rachel L.、Rodriguez-Barraquer Isabel、Greenhouse Bryan、Goldberg Sarah A.、Mathur Sujata、Hoh Rebecca、Fehrman Emily A.、Torres Leonel、Williams Meghann C.、Bautista Jennifer A.、Martinez Enrique O.、Murray Victoria W.、Ellis Payton K.、Massachi Jonathan A.、Weiss Jacob O.、Mehdi Irum、Martin Jeffrey N.、Assenzio Melissa、Sauceda John A.、Gandhi Monica、Hsue Priscilla Y.、Deeks Steven G.、Anglin Khamal A.、Deswal Monika、Krone Melissa、Arreguin Mireya I.、Rugart Paulina R.、Romero Mariela D.、Ngo Lynn H.、Spinelli Matthew A.、Munter Sadie E.、Hernandez Yanel、Lu Scott、Davidson Michelle C.、Tai Viva、Chen Jessica Y.、Durstenfeld Matthew S.、Henrich Timothy J.、Tavs Jacqueline、Tang Alex F.、Sans Hannah M.、Wenger Megan、Donohue Kevin C.、Kelly J. Daniel、Peluso Michael J.
Department of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDivision of Experimental Medicine, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California||Division of Experimental Medicine, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California||Department of Epidemiology and Biostatistics, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaCenter for AIDS Prevention Studies, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDivision of Cardiology, Zuckerberg San Francisco General Hospital, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California||Division of Experimental Medicine, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of California||Division of Experimental Medicine, University of CaliforniaDivision of Cardiology, Zuckerberg San Francisco General Hospital, University of CaliforniaDivision of Experimental Medicine, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of CaliforniaDepartment of Epidemiology and Biostatistics, University of California||Department of Ophthalmology, University of CaliforniaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California
医学研究方法医药卫生理论临床医学
SARS-CoV-2coronavirusCOVID-19post-acute sequelae of SARS-CoV-2 infection (PASC)long COVID
Pineda-Ramirez Jesus,Yuan Yan,Rutishauser Rachel L.,Rodriguez-Barraquer Isabel,Greenhouse Bryan,Goldberg Sarah A.,Mathur Sujata,Hoh Rebecca,Fehrman Emily A.,Torres Leonel,Williams Meghann C.,Bautista Jennifer A.,Martinez Enrique O.,Murray Victoria W.,Ellis Payton K.,Massachi Jonathan A.,Weiss Jacob O.,Mehdi Irum,Martin Jeffrey N.,Assenzio Melissa,Sauceda John A.,Gandhi Monica,Hsue Priscilla Y.,Deeks Steven G.,Anglin Khamal A.,Deswal Monika,Krone Melissa,Arreguin Mireya I.,Rugart Paulina R.,Romero Mariela D.,Ngo Lynn H.,Spinelli Matthew A.,Munter Sadie E.,Hernandez Yanel,Lu Scott,Davidson Michelle C.,Tai Viva,Chen Jessica Y.,Durstenfeld Matthew S.,Henrich Timothy J.,Tavs Jacqueline,Tang Alex F.,Sans Hannah M.,Wenger Megan,Donohue Kevin C.,Kelly J. Daniel,Peluso Michael J..Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19[EB/OL].(2025-03-28)[2025-05-15].https://www.medrxiv.org/content/10.1101/2021.03.11.21252311.点此复制
评论